------------
This article outlines the key differences between Mpox and COVID-19, focusing on transmission, symptoms, and severity. The WHO reassures the public that Mpox is not as contagious or severe as COVID-19, with distinct differences in its spread and impact.
------------
As the World Health Organisation (WHO) works to reassure the global community, it's crucial to understand that Mpox (formerly known as monkeypox) is not the new COVID-19. Here are the key differences:
- Transmission:
- Mpox: Spread primarily through close physical contact, particularly skin-to-skin, and contact with contaminated objects.
- COVID-19: Primarily airborne, spreading through respiratory droplets.
- Symptoms:
- Mpox: Characterised by fever, rash, and swollen lymph nodes, often leading to visible skin lesions.
- COVID-19: Symptoms range from fever, cough, and shortness of breath to loss of taste or smell, and severe cases can lead to respiratory issues.
- Infectivity:
- Mpox: Less contagious, requires prolonged contact, and has limited human-to-human transmission.
- COVID-19: Highly contagious and can spread rapidly in crowded or enclosed spaces.
- Mortality Rate:
- Mpox: Generally low mortality, with most cases being mild.
- COVID-19: Variable, but can be high, especially in older adults or those with underlying health conditions.
- Vaccine Availability:
- Mpox: Vaccines exist, especially for those at higher risk, similar to smallpox vaccines.
- COVID-19: Multiple vaccines are widely available and administered globally.
